摘要
目的观察溃疡性结肠炎(UC)患者大肠湿热证候评分与Mayo活动指数、Th17细胞、Treg细胞的相关性及连草泻痢胶囊对大肠湿热证UC患者的临床疗效。方法分析UC大肠湿热证候评分与Mayo活动指数、Th17细胞、Treg细胞的相关性。美沙拉嗪组予美沙拉嗪缓释颗粒治疗,连草泻痢组则加用连草泻痢胶囊。对两组治疗前后大肠湿热证候评分、Mayo活动指数、Th17细胞、Treg细胞水平进行对比,并评价其临床疗效。结果大肠湿热证候评分与Mayo活动指数、Th17细胞存在显著正相关(P<0.05),与Treg细胞相比存在显著负相关(P<0.05)。治疗后连草泻痢组大肠湿热证候评分、Mayo活动指数、Th17细胞及Th17/Treg细胞比例降幅与Treg细胞升幅均高于美沙拉嗪组(P<0.05),总有效率亦高于美沙拉嗪组(P<0.05)。结论Th17/Treg细胞比例能反应UC大肠湿热证型的严重程度;连草泻痢胶囊联合西药治疗UC效果明显,可能与其调控Th17/Treg细胞比例平衡有关。
Objective To observe the correlation of large intestine damp-heat syndrome score with Mayo activity index,Th17 cells and Treg cells in patients with ulcerative colitis(UC)and the clinical effect of Liancao Xieli capsules on UC patients with large intestine damp-heat syndrome.Methods The correlation between UC large intestine damp-heat syndrome score and Mayo activity index,Th17 cells and Treg cells was analyzed.The mesalazine group was treated with mesalazine sustained release granules,and the Liancao diarrhea group was treated with Liancao diarrhea capsules.The scores of large intestine damp-heat syndrome,Mayo activity index,Th17 cells and Treg cells were compared between the two groups before and after treatment,and the clinical efficacy was evaluated.Results There was a significant positive correlation between the syndrome score of large intestine damp-heat syndrome and Mayo activity index,Th17 cells(P<0.05),and a significant negative correlation with Treg cells(P<0.05).After treatment,the scores of large intestine damp-heat syndrome,Mayo activity index,the decrease of Th17 cells and Th17/Treg cells and the increase of Treg cells in Liancao Xieli group were greater than those in mesalazine group(P<0.05),and the total effective rate was also greater than that in mesalazine group(P<0.05).Conclusion The proportion of Th17/Treg cells can reflect the severity of UC large intestine damp-heat syndrome,the effect of Liancao Xieli capsules combined with western medicine on UC is obvious,which may be related to the regulation of Th17/Treg cell ratio balance.
作者
赵玲玲
袁星星
王炳予
卢科强
张雅丽
ZHAO Lingling;YUAN Xingxing;WANG Bingyu;LU Keqiang;ZHANG Yali(Graduate School,Heilongjiang Academy of Chinese Medical Sciences,Harbin 150036,China;Hepatobiliary Spleen and Stomach DiseaseⅡ,Heilongjiang Academy of Chinese Medical Sciences,Harbin 150006,China)
出处
《现代中药研究与实践》
CAS
2023年第1期70-74,共5页
Research and Practice on Chinese Medicines
基金
黑龙江省卫生健康委科研项目(2020-291)
黑龙江省自然科学基金联合引导项目(LH2019H095)。